title: Updates in thrombosis in pediatrics: where are we after 20 years?
abstract: The incidence of venous thromboembolism (VTE) in the pediatric population is increasing. Technological advances in medicine and imaging techniques, improved awareness of the disease, and longer survival of life-threatening or chronic medical conditions all contribute to the increase in VTE rates. There is a paucity of data on management of VTE based on properly designed clinical trials, but there is significant advancement in the last 2 decades. This review summarizes the progress made in pediatric thrombosis, including epidemiological changes, advances in anticoagulant agents, and outcomes of VTE.
authors.affiliation: McMaster University, Department of Pediatrics, Division of Hematology/Oncology, Rm 3N27, 1280 Main St West, Hamilton, ON, L8S 4K1 Canada. akchan@mcmaster.ca
authors.forename: Anthony K C
authors.initials: AK
authors.lastname: Chan
authors.forename: Paul
authors.initials: P
authors.lastname: Monagle
mesh_terms: D000293:Adolescent; D000925:Anticoagulants / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006405:Hematology / Q000379:methods*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D010372:Pediatrics / Q000379:methods*; D012008:Recurrence; D012306:Risk; D012307:Risk Factors; D013927:Thrombosis / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin